Tolerability/PK study of MAT2203 in patients with a hematologic malignancy

Trial Profile

Tolerability/PK study of MAT2203 in patients with a hematologic malignancy

Planning
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Amphotericin B (Primary)
  • Indications Aspergillosis; Candidiasis; Cryptococcosis; Mycoses; Visceral leishmaniasis; Vulvovaginal candidiasis
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Nov 2017 According to a Matinas BioPharma media release, initial data from the trial is expected in the fourth quarter of 2018.
    • 16 May 2017 According to a Matinas BioPharma media release, this trial is expected to initiate in the third quarter of 2017.
    • 28 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top